KYMR vs. BEAM, DNA, SANA, VCEL, FUSN, RXRX, NMRA, DNLI, CGON, and TWST
Should you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA), Sana Biotechnology (SANA), Vericel (VCEL), Fusion Pharmaceuticals (FUSN), Recursion Pharmaceuticals (RXRX), Neumora Therapeutics (NMRA), Denali Therapeutics (DNLI), CG Oncology (CGON), and Twist Bioscience (TWST). These companies are all part of the "biological products, except diagnostic" industry.
Kymera Therapeutics (NASDAQ:KYMR) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
Beam Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.
99.7% of Beam Therapeutics shares are owned by institutional investors. 16.7% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Beam Therapeutics received 1 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 50.65% of users gave Beam Therapeutics an outperform vote while only 46.91% of users gave Kymera Therapeutics an outperform vote.
Kymera Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.
In the previous week, Kymera Therapeutics and Kymera Therapeutics both had 7 articles in the media. Beam Therapeutics' average media sentiment score of 0.54 beat Kymera Therapeutics' score of 0.40 indicating that Beam Therapeutics is being referred to more favorably in the news media.
Kymera Therapeutics currently has a consensus target price of $41.20, indicating a potential upside of 19.94%. Beam Therapeutics has a consensus target price of $41.00, indicating a potential upside of 70.12%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Kymera Therapeutics.
Beam Therapeutics has a net margin of -35.09% compared to Kymera Therapeutics' net margin of -187.00%. Beam Therapeutics' return on equity of -15.90% beat Kymera Therapeutics' return on equity.
Summary
Beam Therapeutics beats Kymera Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Kymera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kymera Therapeutics Competitors List
Related Companies and Tools
